Contribute Try STAT+ Today

Two years ago, Roche spent $1.9 billion to buy a startup, Flatiron Health, which uses data from patients’ electronic health records to better study cancer drugs. Now, many of the same investors are backing a new firm that will aim to do similar research in eye disease and neurology.

The twist: The new company, Verana Health, is obtaining its data by partnering with medical societies, including the American Academy of Ophthalmology, the largest organization of ophthalmologists, and the American Academy of Neurology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.